ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.
- ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.
- The trial marks the formal start of clinical development of the peanut SLIT-tablet which uses same technology as ALKs SLIT-tablets for respiratory allergies.
- ALK announced today that it is initiating Phase I clinical development of its investigational SLIT-tablet for the treatment of peanut allergy.
- The Alliance trial is a Phase I, open-label, dose-escalation, multi-centre trial, with participants screened via double-blind, placebo-controlled food challenges to confirm their peanut allergy.